{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:41:22Z","timestamp":1774374082080,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.cyto.2023.156459","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T07:25:23Z","timestamp":1701761123000},"page":"156459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["CXCL6 promotes the progression of NAFLD through regulation of PPAR\u03b1"],"prefix":"10.1016","volume":"174","author":[{"given":"Yanli","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yisan","family":"cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cyto.2023.156459_b0005","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cyto.2023.156459_b0010","article-title":"Nonalcoholic fatty liver disease","volume":"169","author":"Wang","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10290","key":"10.1016\/j.cyto.2023.156459_b0015","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cyto.2023.156459_b0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cyto.2023.156459_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111562","article-title":"Pdcd4 promotes lipid deposition by attenuating PPAR\u03b1-mediated fatty acid oxidation in hepatocytes","volume":"545","author":"Du","year":"2022","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.cyto.2023.156459_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","volume":"50","author":"Pafili","year":"2021","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.cyto.2023.156459_b0035","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/hep.24457","article-title":"CXC chemokine signaling in the liver: impact on repair and regeneration","volume":"54","author":"Van Sweringen","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cyto.2023.156459_b0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/15384047.2020.1842705","article-title":"CXCL6 regulates cell permeability, proliferation, and apoptosis after ischemia-reperfusion injury by modulating Sirt3 expression via AKT\/FOXO3a activation","volume":"22","author":"Wang","year":"2021","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.cyto.2023.156459_b0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.24028","article-title":"CXC chemokine receptor-1 is expressed by hepatocytes and regulates liver recovery after hepatic ischemia\/reperfusion injury","volume":"53","author":"Clarke","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cyto.2023.156459_b0050","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.22471","article-title":"Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia\/reperfusion in mice","volume":"48","author":"Kuboki","year":"2008","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cyto.2023.156459_b0055","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1111\/jcmm.13787","article-title":"CXCL6-EGFR-induced Kupffer cells secrete TGF-\u03b21 promoting hepatic stellate cell activation via the SMAD2\/BRD4\/C-MYC\/EZH2 pathway in liver fibrosis","volume":"22","author":"Cai","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.1016\/j.cyto.2023.156459_b0060","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1080\/21655979.2022.2030557","article-title":"Ethanol promoting the upregulation of C-X-C Motif Chemokine Ligand 1(CXCL1) and C-X-C Motif Chemokine Ligand 6(CXCL6) in models of early alcoholic liver disease","volume":"13","author":"Jiang","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.cyto.2023.156459_b0065","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cyto.2023.156459_b0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.biochi.2016.12.019","article-title":"The role and regulation of the peroxisome proliferator activated receptor alpha in human liver","volume":"136","author":"Kersten","year":"2017","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.cyto.2023.156459_b0075","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.cyto.2023.156459_b0080","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1186\/s12864-015-1969-3","article-title":"The impact of PPAR\u03b1 activation on whole genome gene expression in human precision cut liver slices","volume":"16","author":"Janssen","year":"2015","journal-title":"BMC Genomics"},{"key":"10.1016\/j.cyto.2023.156459_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD","volume":"115","author":"Sun","year":"2021","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.cyto.2023.156459_b0090","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3748\/wjg.v25.i11.1307","article-title":"Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice","volume":"25","author":"Zhou","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.cyto.2023.156459_b0095","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41575-018-0065-y","article-title":"Apoptosis and necroptosis in the liver: a matter of life and death","volume":"15","author":"Schwabe","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cyto.2023.156459_b0100","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cyto.2023.156459_b0105","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1002\/hep.32075","article-title":"SIMPLE Is an endosomal regulator that protects against NAFLD by targeting the lysosomal degradation of EGFR","volume":"74","author":"Song","year":"2021","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.cyto.2023.156459_b0110","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.21037\/atm-21-5767","article-title":"Y-box binding protein 1 regulates liver lipid metabolism by regulating the Wnt\/\u03b2-catenin signaling pathway","volume":"9","author":"Ma","year":"2021","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.cyto.2023.156459_b0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12986-021-00634-4","article-title":"The role and possible mechanism of the long noncoding RNA LINC01260 in nonalcoholic fatty liver disease","volume":"19","author":"Ge","year":"2022","journal-title":"Nutr Metab (lond)"},{"issue":"4","key":"10.1016\/j.cyto.2023.156459_b0120","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11154-023-09800-w","article-title":"A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver disease","volume":"24","author":"Ullah","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"10.1016\/j.cyto.2023.156459_b0125","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/hep.31031","article-title":"Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets","volume":"72","author":"Hwang","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cyto.2023.156459_b0130","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1038\/s41598-018-29735-6","article-title":"Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin","volume":"8","author":"Ogawa","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cyto.2023.156459_b0135","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3389\/fimmu.2020.01802","article-title":"Chemokines in Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.cyto.2023.156459_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110286","article-title":"Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-\u03baB pathway","volume":"128","author":"Chen","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"25","key":"10.1016\/j.cyto.2023.156459_b0145","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.3748\/wjg.v24.i25.2661","article-title":"Apoptosis and non-alcoholic fatty liver diseases","volume":"24","author":"Kanda","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cyto.2023.156459_b0150","first-page":"696","article-title":"miR-122-5p\/KIF5B\/AMPK\/AKT regulatory network regulates the progression of NAFLD","volume":"13","author":"Zhang","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.cyto.2023.156459_b0155","doi-asserted-by":"crossref","first-page":"1118449","DOI":"10.3389\/fimmu.2023.1118449","article-title":"Programmed cell death and lipid metabolism of macrophages in NAFLD","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.cyto.2023.156459_b0160","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cyto.2023.156459_b0165","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1440-1746.2011.06939.x","article-title":"Peroxisome proliferator-activated receptor-\u03b1 agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis","volume":"27","author":"Larter","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cyto.2023.156459_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12010055","article-title":"Lentinan protects against nonalcoholic fatty liver disease by reducing oxidative stress and apoptosis via the PPAR\u03b1 pathway","volume":"12","author":"Du","year":"2022","journal-title":"Metabolites"},{"issue":"10","key":"10.1016\/j.cyto.2023.156459_b0175","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cyto.2023.156459_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113577","article-title":"A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPAR\u03b1) and farnesoid X receptor (FXR)","volume":"154","author":"Zhou","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.cyto.2023.156459_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052668","article-title":"Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease","volume":"23","author":"Puengel","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cyto.2023.156459_b0190","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J Hepatol"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104346662300337X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104346662300337X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T09:47:00Z","timestamp":1736329620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104346662300337X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":38,"alternative-id":["S104346662300337X"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156459","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCL6 promotes the progression of NAFLD through regulation of PPAR\u03b1","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"156459"}}